Đang chuẩn bị liên kết để tải về tài liệu:
Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) – a prospective, randomized, 2-armed phase-II-trial

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG Tải xuống

The incidence of anal cancer is rising in the last decades and more women are affected than men. The prognosis after chemoradiation is very good with complete remission rates of 80–90%. Thus, reducing therapyrelated toxicities and improving quality of life are of high importance. | Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy DILANA a prospective randomized 2-armed phase-II-trial